ATE215829T1 - Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus - Google Patents

Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus

Info

Publication number: ATE215829T1
Authority: AT; Austria
Prior art keywords: heparin; chitosan; herpes virus; prevent; infections caused
Prior art date: 1996-08-06

Application number

AT97934838T

Other languages

English (en)

Inventor

Olle Larm

Marcus Back

Tomas Bergstroem

Original Assignee

Medicarb Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-06

Filing date

1997-08-01

Publication date

2002-04-15

1997-08-01 Application filed by Medicarb Ab filed Critical Medicarb Ab

2002-04-15 Application granted granted Critical

2002-04-15 Publication of ATE215829T1 publication Critical patent/ATE215829T1/de

Links

241001529453 unidentified herpesvirus Species 0.000 title abstract 3
229920001661 Chitosan Polymers 0.000 title abstract 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 2
229920000669 heparin Polymers 0.000 title abstract 2
229960002897 heparin Drugs 0.000 title abstract 2
208000015181 infectious disease Diseases 0.000 title abstract 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title 1
208000035473 Communicable disease Diseases 0.000 abstract 1
229920002971 Heparan sulfate Polymers 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicinal Preparation (AREA)

AT97934838T 1996-08-06 1997-08-01 Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus ATE215829T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9602931A SE507028C2 (sv)	1996-08-06	1996-08-06	Ny medicinsk användning
PCT/SE1997/001320 WO1998005341A1 (en)	1996-08-06	1997-08-01	The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus

Publications (1)

Publication Number	Publication Date
ATE215829T1 true ATE215829T1 (de)	2002-04-15

Family

ID=20403528

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97934838T ATE215829T1 (de)	1996-08-06	1997-08-01	Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus

Country Status (13)

Country	Link
US (1)	US6207653B1 (de)
EP (1)	EP0930885B1 (de)
JP (1)	JP2000515543A (de)
CN (1)	CN1227493A (de)
AT (1)	ATE215829T1 (de)
AU (1)	AU705189B2 (de)
CA (1)	CA2261742A1 (de)
DE (1)	DE69711897T2 (de)
DK (1)	DK0930885T3 (de)
ES (1)	ES2174273T3 (de)
NZ (1)	NZ333925A (de)
SE (1)	SE507028C2 (de)
WO (1)	WO1998005341A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE508760C2 (sv)	1997-04-29	1998-11-02	Medicarb Ab	Användning av en komposition innefattande kitosan i kombination med en polysackarid, som aktiv komponent i ett lösningsmedel, för framställning av ett spendoppningsmedel för mjölkproducerande djur
AU7070700A (en) *	1999-08-25	2001-03-19	Massachusetts Institute Of Technology	Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
US6977248B1 (en) *	1999-08-25	2005-12-20	Massachusetts Institute Of Technology	Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry
SE9904289D0 (sv) *	1999-11-26	1999-11-26	Niklas Arnberg	Method and camposition for the treatment of adenovairal ocular infections
US20020119949A1 (en) *	2001-02-26	2002-08-29	Asa Hellman	Prophylactic teat treatment
US7968122B2 (en) *	2003-12-10	2011-06-28	Adventrx Pharmaceuticals, Inc.	Anti-viral pharmaceutical compositions
EP1774971A1 (de) *	2005-10-14	2007-04-18	Advanced in Vitro Cell Technologies, S.L.	Nanopartikel enthaltend Chitosan und Heparin
KR101397386B1 (ko) *	2005-12-13	2014-05-26	엑스테라 메디컬 코퍼레이션	혈액으로부터 병원성 미생물, 염증 세포 또는 염증단백질의 체외 제거를 위한 방법
WO2008155683A1 (en)	2007-06-18	2008-12-24	Firmenich Sa	Malodor counteracting compositions and method for their use
CL2008000156A1 (es) *	2008-01-18	2008-08-01	Igloo Zone Chile S A	Gel estable hidrofilo en base a un polimero para aplicacion topica porque comprende quitosano disuelto en un solvente; proceso para obtener el gel para uso topico antes mencionado; uso del gel.
CN102458419A (zh) *	2009-06-10	2012-05-16	埃克塞拉医学有限责任公司	组合物用于治疗粘膜炎的用途
ES2861359T3 (es)	2009-12-01	2021-10-06	Exthera Medical Corp	Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
US20110212181A1 (en) *	2010-02-26	2011-09-01	The University Of Hong Kong	Compositions and methods for treating chronic respiratory inflammation
DK2557151T3 (en) *	2010-04-07	2017-12-11	Mitsubishi Gas Chemical Co	S-adenosyl-L-methionine-containing dry yeast composition with excellent storage stability and process for preparing the same
JPWO2011142484A1 (ja) *	2010-05-14	2013-07-22	株式会社日本触媒	ポリアルキレンイミンを含むウイルス感染症治療薬
WO2012112724A1 (en)	2011-02-15	2012-08-23	Exthera Medical, Llc	Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
EP2861273B1 (de)	2012-06-13	2017-08-23	ExThera Medical Corporation	Verwendung von heparin und kohlenhydraten zur behandlung von krebs
BR112015032134B1 (pt)	2013-06-24	2022-05-10	Exthera Medical Corporation	Método de ligação em ponto de extremidade de uma manose não redutora a um substrato e esfera possuindo uma manose ligada em ponto de extremidade
BR112016009827B1 (pt)	2013-11-08	2021-10-26	Exthera Medical Corporation	Método in vitro para concentrar patógenos infecciosos presentes em uma amostra biológica obtida a partir de um indivíduo sob suspeita de estar infectado com os ditos patógenos, concentrador e kit
EP3134146B1 (de)	2014-04-24	2024-12-25	ExThera Medical Corporation	Verfahren zur entfernung von bakterien aus blut unter verwendung einer hohen durchflussrate
US10857283B2 (en)	2014-09-22	2020-12-08	Exthera Medical Corporation	Wearable hemoperfusion device
WO2017151797A1 (en)	2016-03-02	2017-09-08	Exthera Medical Corporation	Method for treating drug intoxication
US11911551B2 (en)	2016-03-02	2024-02-27	Exthera Medical Corporation	Method for treating drug intoxication
WO2020231830A1 (en)	2019-05-16	2020-11-19	Exthera Medical Corporation	Method for modulating endothelial glycocalyx structure
EP4228595A1 (de) *	2020-10-14	2023-08-23	Medoderm GmbH	Flüssige zusammensetzung zur verwendung bei der vorbeugung oder verminderung von hautreizungen, allergien und/oder infektionskrankheiten
EP4401784A4 (de) *	2021-09-17	2025-09-10	Shawn Walker	Verwendung von chitosankomplexen oder zusammensetzungen zur verringerung der infiltration von umweltfaktoren in das gehirn

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU77562A1 (de) *	1977-06-17	1979-03-26	Ciba Geigy Ag	Verfahren zur herstellung von neuen pharmazeutischen praeparaten
EP0240098A3 (de)	1986-04-04	1989-05-10	Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo	Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
AU1052492A (en)	1991-01-31	1992-08-06	Farmitalia Carlo Erba S.R.L.	Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent

1996
- 1996-08-06 SE SE9602931A patent/SE507028C2/sv not_active IP Right Cessation
1997
- 1997-08-01 DK DK97934838T patent/DK0930885T3/da active
- 1997-08-01 NZ NZ333925A patent/NZ333925A/xx unknown
- 1997-08-01 AU AU37911/97A patent/AU705189B2/en not_active Ceased
- 1997-08-01 EP EP97934838A patent/EP0930885B1/de not_active Expired - Lifetime
- 1997-08-01 DE DE69711897T patent/DE69711897T2/de not_active Expired - Fee Related
- 1997-08-01 WO PCT/SE1997/001320 patent/WO1998005341A1/en not_active Ceased
- 1997-08-01 CA CA002261742A patent/CA2261742A1/en not_active Abandoned
- 1997-08-01 US US09/230,021 patent/US6207653B1/en not_active Expired - Fee Related
- 1997-08-01 AT AT97934838T patent/ATE215829T1/de not_active IP Right Cessation
- 1997-08-01 JP JP10507859A patent/JP2000515543A/ja active Pending
- 1997-08-01 CN CN97197038A patent/CN1227493A/zh active Pending
- 1997-08-01 ES ES97934838T patent/ES2174273T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CN1227493A (zh)	1999-09-01
AU705189B2 (en)	1999-05-20
US6207653B1 (en)	2001-03-27
EP0930885B1 (de)	2002-04-10
WO1998005341A1 (en)	1998-02-12
DE69711897T2 (de)	2002-08-22
SE9602931D0 (sv)	1996-08-06
CA2261742A1 (en)	1998-02-12
NZ333925A (en)	2000-07-28
SE507028C2 (sv)	1998-03-16
DE69711897D1 (de)	2002-05-16
AU3791197A (en)	1998-02-25
SE9602931L (sv)	1998-02-07
EP0930885A1 (de)	1999-07-28
JP2000515543A (ja)	2000-11-21
DK0930885T3 (da)	2002-05-06
ES2174273T3 (es)	2002-11-01

Similar Documents

Publication	Publication Date	Title
ATE215829T1 (de)	2002-04-15	Die verwendung von heparin oder heparansulfat kombiniert mit chitosan zur vorbeugung oder behandlung von infektionen verursacht durch den herpes-virus
ATE266417T1 (de)	2004-05-15	Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
PT646012E (pt)	2003-03-31	Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
BR9306040A (pt)	1997-11-18	Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
ATE205389T1 (de)	2001-09-15	Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
ATE213411T1 (de)	2002-03-15	Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69232911D1 (de)	2003-03-06	Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
ATE94760T1 (de)	1993-10-15	Sulfatierte vinylpolymere in praeparaten zur behandlung von retroviralen infektionen.
DE69004451D1 (de)	1993-12-16	Prophylaxe und Behandlung von Herpesvirus-Infektionen.
BR9406548A (pt)	1996-01-02	Composto para emprego como produto farmacêutico composto para emprego no tratamento ou prevenção de câncer e pré-câncer ou de doenças causadas por infecçao viral composto para emprego no tratamento ou prãvençao de câncer ou de pré-câncer composto para emprego no tratamento ou prevenção de doenças causadas por infecção viral composiçao farmacêutica processo para tratar doenças causadas por infecção viral processo de tratamento de câncer ou pré-câncer composto de ácido clorobenzenossulfônico ou ni
DE50100833D1 (de)	2003-11-27	Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
SE9303612D0 (sv)	1993-11-02	New use
DE69003960D1 (de)	1993-11-25	Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
ATE204476T1 (de)	2001-09-15	Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazi e zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
ATE316789T1 (de)	2006-02-15	Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen
DE69623316D1 (de)	2002-10-02	Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE284209T1 (de)	2004-12-15	Verwendung einer pharmazeutischen zusammensetzung zur herstellung eines medikamentes zur behandlung von durch bakterien, viren, pilze, hefen und/oder protozoen verursachten augenerkrankungen
ATE295159T1 (de)	2005-05-15	Bupropion zur behandlung von viralen erkrankungen
MX2022012487A (es)	2023-02-09	Métodos para tratar y/o prevenir infecciones y/o enfermedades virales causadas por virus en un sujeto que lo necesita.
ATE255417T1 (de)	2003-12-15	Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE335494T1 (de)	2006-09-15	Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
RU98121717A (ru)	2000-09-10	Способ лечения аллергических заболеваний
DE69210737D1 (de)	1996-06-20	Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
DE59504374D1 (de)	1999-01-14	Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
ATE107166T1 (de)	1994-07-15	Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.

Legal Events

Date	Code	Title	Description
2002-08-15	UEP	Publication of translation of european patent specification
2003-11-15	REN	Ceased due to non-payment of the annual fee